Back to search

Peptide record

TPDB14963

ACE Inhibitor ACE inhibitors Antibacterial Anticancer Antifungal Antihypertensive Antiviral Cell-penetrating Peptides Hemolysis Toxicity standard
6 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB14963
ACE Inhibitor
ACE inhibitors Antibacterial Anticancer Antifungal Antihypertensive Antiviral Cell-penetrating Peptides Hemolysis Toxicity
Anti-infective peptides Cardiometabolic peptides Cancer-related peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides
Peptipedia dbAMP DRAMP CAFPdb AHTPDB AHTpin dbAMP 3.0 CPPsite3.0 PD_Hemolysis
standard
No
A 6-aa standard natural multi-activity (ACE inhibitors, Antibacterial, Anticancer, and other sources) peptide sequence curated from Peptipedia, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
RRWQWR
Physicochemical Analysis
C45H66N18O8
ANDCEGHILKMFPSTYV
R
987.13
12.70
3
0
2
+3
-0.69
-3.133
0.00
Mammalian: 1 hour Yeast: 2 min E.coli: 2 min
11000
1114.34
1
Residue Composition
number
0
A
3
R
0
N
0
D
0
C
0
E
1
Q
0
G
0
H
0
I
0
L
0
K
0
M
0
F
0
P
0
S
0
T
2
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 3 N: 0 D: 0 C: 0 E: 0 Q: 1 G: 0 H: 0 I: 0 L: 0 K: 0 M: 0 F: 0 P: 0 S: 0 T: 0 W: 2 Y: 0 V: 0
Chemical Descriptors
6
C45H66N18O8
987.13
12.70
+3
-0.69
-3.133
987.1187
986.5298
Evidence Records 21 records
Evidence 1 Activity

Activity

IC50
ACE inhibitors
0.00 µM
Inhibitor of Angiotensin-converting enzyme (EC 3.4.15.1) (MEROPS ID: M02-001)
ACE inhibitor
ah

Source & Reference

NA
Ruiz-Giménez P., Ibáñez A., Salom J. B., Marcos J. F., López-Díez J. J., Vallés S., Torregrosa G., Alborch E., Manzanares P.,
Antihypertensive properties of lactoferricin B-derived peptides. J. Agric. Food Chem., 58, 6721-6727, 2010
2010
Journal

Other

6
BIOPEP-UWM database of bioactive peptides SMILES: N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC1=C[N]([H])C2=CC=CC=C12)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC3=C[N]([H])C4=CC=CC=C34)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O InChI=1S/C45H66N18O8/c46-28(10-5-17-54-43(48)49)37(65)59-31(13-6-18-55-44(50)51)38(66)62-34(20-24-22-57-29-11-3-1-8-26(24)29)40(68)60-32(15-16-36(47)64)39(67)63-35(21-25-23-58-30-12-4-2-9-27(25)30)41(69)61-33(42(70)71)14-7-19-56-45(52)53/h1-4,8-9,11-12,22-23,28,31-35,57-58H,5-7,10,13-21,46H2,(H2,47,64)(H,59,65)(H,60,68)(H,61,69)(H,62,66)(H,63,67)(H,70,71)(H4,48,49,54)(H4,50,51,55)(H4,52,53,56)/t28-,31-,32-,33-,34-,35-/m0/s1 InChIKey: ATQXVDLVDPHGEX-DATVRVMLSA-N Antibacterial peptide according to the BIOPEP-UWM database of bioactive peptides (ID 9457) ________________________________________
Evidence 2 Activity

Activity

MIC
Antibacterial
7.5 µM

Target

B. subtilis ATCC6633

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
Active against B. subtilis ATCC6633 (MIC 7.5 uM), S. aureus 42D (MIC 30 uM), and E. coli ML35 (MIC 60 uM) ( Nguyen et al., 2010 ). Nonstan
Evidence 3 Activity

Activity

MIC
Antibacterial
30 µM

Target

Staphylococcus aureus 42D

Source & Reference

dbAMP DRAMP

Other

Active against B. subtilis ATCC6633 (MIC 7.5 uM), S. aureus 42D (MIC 30 uM), and E. coli ML35 (MIC 60 uM) ( Nguyen et al., 2010 ). Nonstandard assays in 1% TSB.
Evidence 4 Activity

Activity

MIC
Antibacterial
60 µM

Target

Escherichia coli ML35

Source & Reference

dbAMP DRAMP

Other

Active against B. subtilis ATCC6633 (MIC 7.5 uM), S. aureus 42D (MIC 30 uM), and E. coli ML35 (MIC 60 uM) ( Nguyen et al., 2010 ). Nonstandard assays in 1% TSB.
Evidence 5 Activity

Activity

MIC
Antifungal
7.5 µM

Target

B. subtilis ATCC6633

Source & Reference

dbAMP DRAMP CAFPdb

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
Active against B. subtilis ATCC6633 (MIC 7.5 uM), S. aureus 42D (MIC 30 uM), and E. coli ML35 (MIC 60 uM) ( Nguyen et al., 2010 ). Nonstan
Evidence 6 Activity

Activity

MIC
Antifungal
30 µM

Target

Staphylococcus aureus 42D

Source & Reference

dbAMP DRAMP CAFPdb

Other

Active against B. subtilis ATCC6633 (MIC 7.5 uM), S. aureus 42D (MIC 30 uM), and E. coli ML35 (MIC 60 uM) ( Nguyen et al., 2010 ). Nonstandard assays in 1% TSB.
Evidence 7 Activity

Activity

MIC
Antifungal
60 µM

Target

Escherichia coli ML35

Source & Reference

dbAMP DRAMP CAFPdb

Other

Active against B. subtilis ATCC6633 (MIC 7.5 uM), S. aureus 42D (MIC 30 uM), and E. coli ML35 (MIC 60 uM) ( Nguyen et al., 2010 ). Nonstandard assays in 1% TSB.
Evidence 8 Activity

Activity

IC50
Antihypertensive
0.00 µM
Inhibitor of Angiotensin-converting enzyme (EC 3.4.15.1) (MEROPS ID: M02-001)
ACE inhibitor
ah

Source & Reference

AHTPDB
Ruiz-Giménez P., Ibáñez A., Salom J. B., Marcos J. F., López-Díez J. J., Vallés S., Torregrosa G., Alborch E., Manzanares P.,
Antihypertensive properties of lactoferricin B-derived peptides. J. Agric. Food Chem., 58, 6721-6727, 2010
2010
Journal

Other

Source Activity Label Source Definition
Antihypertensive
AHTPDB manually curated experimentally validated antihypertensive peptide annotation.
6
BIOPEP-UWM database of bioactive peptides SMILES: N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC1=C[N]([H])C2=CC=CC=C12)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC3=C[N]([H])C4=CC=CC=C34)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O InChI=1S/C45H66N18O8/c46-28(10-5-17-54-43(48)49)37(65)59-31(13-6-18-55-44(50)51)38(66)62-34(20-24-22-57-29-11-3-1-8-26(24)29)40(68)60-32(15-16-36(47)64)39(67)63-35(21-25-23-58-30-12-4-2-9-27(25)30)41(69)61-33(42(70)71)14-7-19-56-45(52)53/h1-4,8-9,11-12,22-23,28,31-35,57-58H,5-7,10,13-21,46H2,(H2,47,64)(H,59,65)(H,60,68)(H,61,69)(H,62,66)(H,63,67)(H,70,71)(H4,48,49,54)(H4,50,51,55)(H4,52,53,56)/t28-,31-,32-,33-,34-,35-/m0/s1 InChIKey: ATQXVDLVDPHGEX-DATVRVMLSA-N Antibacterial peptide according to the BIOPEP-UWM database of bioactive peptides (ID 9457) ________________________________________
Evidence 9 Activity

Activity

MIC
Antiviral
7.5 µM

Target

B. subtilis ATCC6633

Source & Reference

dbAMP 3.0 DRAMP

Other

Source Activity Label Source Definition
Antiviral
DRAMP antiviral activity supported by activity records against viral targets. dbAMP 3.0 classified under the Anti-viral function class.
Active against B. subtilis ATCC6633 (MIC 7.5 uM), S. aureus 42D (MIC 30 uM), and E. coli ML35 (MIC 60 uM) ( Nguyen et al., 2010 ). Nonstan
Evidence 10 Activity

Activity

MIC
Antiviral
30 µM

Target

Staphylococcus aureus 42D

Source & Reference

dbAMP 3.0 DRAMP

Other

Active against B. subtilis ATCC6633 (MIC 7.5 uM), S. aureus 42D (MIC 30 uM), and E. coli ML35 (MIC 60 uM) ( Nguyen et al., 2010 ). Nonstandard assays in 1% TSB.
Evidence 11 Activity

Activity

MIC
Antiviral
60 µM

Target

Escherichia coli ML35

Source & Reference

dbAMP 3.0 DRAMP

Other

Active against B. subtilis ATCC6633 (MIC 7.5 uM), S. aureus 42D (MIC 30 uM), and E. coli ML35 (MIC 60 uM) ( Nguyen et al., 2010 ). Nonstandard assays in 1% TSB.
Evidence 12 Activity

Activity

<5% Hemolysis
Toxicity
100 µM
Hemolytic Cytotoxic
<5% Hemolysis | 100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Effect of Polyvalence on the Antibacterial Activity of a Synthetic Peptide Derived from Bovine Lactoferricin against Healthcare-Associated Infectious Pathogens. | Biomed Res Int | 2018
Evidence 13 Activity

Activity

50% Hemolysis
Toxicity
>100 µM
Hemolytic Cytotoxic
50% Hemolysis | >100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design, Synthesis and Evaluation of Branched RRWQWR-Based Peptides as Antibacterial Agents Against Clinically Relevant Gram-Positive and Gram-Negative Pathogens. | Front Microbiol | 2018
Evidence 14 Activity

Activity

14% Hemolysis
Toxicity
11 µM
Hemolytic Cytotoxic
14% Hemolysis | 11 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Synergistic bactericide and antibiotic effects of dimeric, tetrameric, or palindromic peptides containing the RWQWR motif against Gram-positive and Gram-negative strains | RSC Adv | 2019
Evidence 15 Activity

Activity

22% Hemolysis
Toxicity
22 µM
Hemolytic Cytotoxic
22% Hemolysis | 22 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Synergistic bactericide and antibiotic effects of dimeric, tetrameric, or palindromic peptides containing the RWQWR motif against Gram-positive and Gram-negative strains | RSC Adv | 2019
Evidence 16 Activity

Activity

Toxicity
Hemolytic Cytotoxic
- | NA | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Serum stabilities of short tryptophan- and arginine-rich antimicrobial peptide analogs. | PLoS One | 2010
Evidence 17 Activity

Activity

7.1% Hemolysis
Toxicity
25 µM
Hemolytic Cytotoxic
7.1% Hemolysis | 25 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Effect of Polyvalence on the Antibacterial Activity of a Synthetic Peptide Derived from Bovine Lactoferricin against Healthcare-Associated Infectious Pathogens. | Biomed Res Int | 2018
Evidence 18 Activity

Activity

Toxicity
Hemolytic
NA | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Serum stabilities of short tryptophan- and arginine-rich antimicrobial peptide analogs. | PLoS One | 2010
Evidence 19 Activity

Activity

10% Hemolysis
Toxicity
>128 µM
Hemolytic Cytotoxic
10% Hemolysis | >128 | µM | target cell: Sheep erythrocytes

Target

Sheep erythrocytes

Source & Reference

NA
DBAASP
A novel hybrid peptide composed of LfcinB6 and KR-12-a4 with enhanced antimicrobial, anti-inflammatory and anti-biofilm activities. | Sci Rep | 2022
Evidence 20 Activity

Activity

% Hemolysis
Toxicity
3 %
Hemolytic
Hemolytic_activity: [Ref.29984236] 3% hemolysis at 5 µM, 5% hemolysis at 12 µM, 5% hemolysis at 22 µM, 0% hemolysis at 50 µM, 2% hemolysis at 100 µM against human red blood cell.##[Ref.29551999] 7.1% hemolysis at 25µM, 50% hemolysis at >100µM against human red blood cells.

Target

erythrocytes

Source & Reference

NA
DRAMP
Biomed Res Int. 2018 Jun 10 2018:5252891##Front Microbiol. 2018 Mar 2 9:329.##PLoS One. 2010 Sep 10 5(9):e12684. doi: 10.1371/journal.pone.0012684
Evidence 21 Hemolysis

Source & Reference

PD_Hemolysis
PD_Hemolysis
Additional Detail Fields 1 fields
6